Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
Latigo Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Latigo Biotherapeutics's cash was $401.24M at Sep 30, 2026. For fiscal 2025 it was $69.44M, up 287.5% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.44M | +287.5% |
| FY2024 | Dec 31, 2024 | $17.92M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $401.24M | +438.6% |
| Q2 FY2026 | Jun 30, 2026 | $55.00M | +207.0% |
| Q4 FY2025 | Dec 31, 2025 | $69.44M | – |
| Q3 FY2025 | Sep 30, 2025 | $104.64M | – |
| Q2 FY2025 | Jun 30, 2025 | $74.50M | – |
| Q4 FY2024 | Dec 31, 2024 | $17.92M | – |
See a number that looks wrong?